Riluzole Oral Suspension shortage
Current 4 presentations · 1 manufacturers · first FDA posting 2024-01-26 · last update 2026-10-15
Manufacturers: EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)
Stated reasons (per FDA): Requirements related to complying with good manufacturing practices
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1) | EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | Current Unavailable |
Requirements related to complying with good manufacturing practices | Estimated recovery: TBD | Posted 01/26/2024 Updated 10/15/2026 |
| Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1) | EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | Current Available |
— | Posted 01/26/2024 Updated 10/15/2026 | |
| Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1) | EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | Current Available |
— | Posted 01/26/2024 Updated 10/15/2026 | |
| Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1) | EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) | Current Available |
— | Posted 01/26/2024 Updated 10/15/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)